Radius Health, Inc. (NASDAQ:RDUS)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $23.09 and last traded at $22.57, with a volume of 5121 shares trading hands. The stock had previously closed at $22.56.
Several brokerages recently issued reports on RDUS. JPMorgan Chase & Co. initiated coverage on Radius Health in a report on Tuesday, September 29th. They set a “neutral” rating for the company. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a report on Saturday, January 9th. HC Wainwright reaffirmed a “hold” rating on shares of Radius Health in a research report on Thursday, January 7th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their price target on shares of Radius Health from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, January 7th. Finally, Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Monday. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Radius Health has an average rating of “Hold” and an average target price of $22.60.
The company has a market cap of $1.03 billion, a price-to-earnings ratio of -7.49 and a beta of 1.07. The business’s 50 day moving average price is $17.63 and its 200-day moving average price is $14.16.
A number of large investors have recently made changes to their positions in the business. Voloridge Investment Management LLC purchased a new stake in shares of Radius Health in the third quarter worth about $512,000. Jane Street Group LLC acquired a new position in shares of Radius Health during the third quarter worth $286,000. Cubist Systematic Strategies LLC grew its stake in shares of Radius Health by 109.1% during the third quarter. Cubist Systematic Strategies LLC now owns 55,761 shares of the biopharmaceutical company’s stock worth $632,000 after purchasing an additional 29,090 shares in the last quarter. Camber Capital Management LP grew its stake in shares of Radius Health by 453.3% during the third quarter. Camber Capital Management LP now owns 2,075,000 shares of the biopharmaceutical company’s stock worth $23,531,000 after purchasing an additional 1,700,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Radius Health in the third quarter valued at $444,000.
About Radius Health (NASDAQ:RDUS)
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer.
Read More: Why are trading ranges significant?
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.